People, Venture Capital

Scientist-turned-VC: Kevin Bitterman takes his biotech hatching experience to a new role at Atlas

Kevin Bitterman knows a thing or two about biotech startups.

Kevin Bitterman

As a partner at Polaris, which specializes in creating cutting edge developers, he was the founding CEO of Editas $EDIT, one of the leaders in the gene editing field. He was present at the creation of Morphic and co-founded Genocea $GNCA, among others.

And now he tells us he is moving over to Atlas Venture, which plays a high profile role in kickstarting its own biotech ventures with a careful eye on the potential payout.

I asked Atlas’ Bruce Booth what inspired the firm to recruit Bitterman. His response:

Kevin is an experienced and accomplished investor who shares our passion for company creation, having helped cofound a number of successful biotechs during his tenure at Polaris. As a scientist-turned-VC, he also embraces our mission of “doing well by doing good” with a focus on transformational rather than incremental biomedical advances. Plus he’s a fantastic human being.

As you well note, he fits right into our seed-led venture creation strategy and brings complementary skills and capacity to the firm.

I asked Bitterman how he would define success in his new role. His reply:

Success to me is pretty simple. Having the world’s best life science entrepreneurs trust us with their ideas and as long term stewards of their science. Being seen as passionate company builders and as thoughtful, diligent partners to the entrepreneurs, operators and co-investors (including my good friends at Polaris) who we’re lucky enough to work with. Hopefully that formula allows us to build some companies that will ultimately change medicine for the better and have a real impact on patients’ lives.

You can watch their progress in creating new companies here at Endpoints News. Bitterman and Booth have the money and the know-how to boot up a string of new biotechs in the next few years. That should be fun to watch.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Bulletin Healthcare

RAPS Fundamentals